Galatea Bio

Galatea Bio Inc. is a Miami-based biotechnology company building the largest longitudinal cohort in the Americas to advance precision health for diverse and underserved populations. The company operates a CLIA-certified, CAP-accredited high-complexity next-generation sequencing molecular diagnostics laboratory and biobank, leveraging one of the largest private genomic-phenotypic data lakes and a world-class team of population geneticists and bioinformatics experts. Galatea Bio partners with leading pharmaceutical and life sciences organizations to design and execute large-scale population sequencing program consortiums in collaboration with academic universities and health systems globally, with a focus on Latin American, Hispanic/Latino, Black or African American, and other underrepresented populations. Founded in 2020, the company has raised $25M to sequence the genetic diversity of 10 million people.